Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

News Conference News ESC 2025

Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support

Todd Neale

August 30, 2025

News Daily News

Sotagliflozin Reduces Ischemic Risk in SCORED Analysis

Yael L. Maxwell

February 25, 2025

News Daily News

Top Heart Failure News of 2023

Shelley Wood

January 05, 2024

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

Caitlin E. Cox

August 30, 2023

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Shelley Wood

May 30, 2023

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Conference News ESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

Todd Neale

August 27, 2022

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

L.A. McKeown

April 07, 2022

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Caitlin E. Cox

December 28, 2021

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

Shelley Wood

November 14, 2021

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

Shelley Wood

October 08, 2021

Podcast TCTMD Talking Points

The SOLOIST-WHF and SCORED Trials

September 08, 2021

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Todd Neale

July 06, 2021

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

Presentation ACC 2021

Benefits of SGLT1/2 Inhibition with Sotagliflozin in Heart Failure With Preserved Ejection Fraction

Presenter: Deepak L. Bhatt

May 17, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2020

Shelley Wood

November 30, 2020

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

Advertisement

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support

Sotagliflozin Reduces Ischemic Risk in SCORED Analysis

Top Heart Failure News of 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

The SOLOIST-WHF and SCORED Trials

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Benefits of SGLT1/2 Inhibition with Sotagliflozin in Heart Failure With Preserved Ejection Fraction

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

TCTMD’s Top 10 Most Popular Stories for November 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content